Literature DB >> 6094198

Ultrastructural studies on human lymphoblastoid cells treated with n-butyrate and 12-O-tetradecanoylphorbol-13-acetate.

S Asai, I Namikawa, Y Ito.   

Abstract

The effects of n-butyrate and/or 12-O-tetradecanoylphorbol-13-acetate (TPA) on Raji and P3HR-1 cells were examined using electron microscopy. n-Butyrate treatment caused a decrease in the number and elongation of surface microvilli. In addition, well-developed rough endoplasmic reticulum and a marked decrease in condensed chromatin clumps were observed in the nucleus. The filamentous structures and nuclear membrane-like structures, which were not reported previously, appeared occasionally in the nucleus. On the other hand, in the cells treated with TPA no marked morphological changes were observed except the higher cytoplasmic:nuclear ratio. n-Butyrate-induced morphological changes were not inhibited when combined with TPA or retinoic acid. Electron microscopic studies showed remarkable differences in morphological change in these cells treated with n-butyrate and/or TPA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094198     DOI: 10.1016/0277-5379(84)90147-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Quantitative analysis of the Epstein-Barr virus-inducing properties of short-chain fatty acids present in the culture fluids of oral bacteria.

Authors:  S Asai; Y Nakamura; M Yamamura; H Ikezawa; I Namikawa
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Ultrastructural studies on cell fusion induced by Epstein-Barr virus or N-butyrate and 12-O-tetradecanoylphorbol-13-acetate. Brief report.

Authors:  S Asai; G J Bayliss; H Wolf; I Namikawa; Y Ito
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

3.  Biochemical and ultrastructural alterations accompany the anti-proliferative effect of butyrate on melanoma cells.

Authors:  J Nordenberg; L Wasserman; A Peled; Z Malik; K H Stenzel; A Novogrodsky
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.